Bcma (original) (raw)

Latest News for: bcma

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases (Form 8-K) (Cullinan Therapeutics Inc)

Public Technologies 10 Jun 2026

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases ... Initial velinotamig (BCMA TCE) data show promising ...

Edit

Imviva Biotech Receives FDA Investigational New Drug Approval for CTA313, a Dual-Targeted CD19/BCMA Allogeneic CAR-T ...

Nasdaq Globe Newswire 09 Jun 2026

Approval paves the way for CTA313 clinical study in the United States ...

Edit

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Hastings Tribune 22 Apr 2026

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s ...

Edit

B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026 - Worth $18.75 Billion in 2026, ...

Nasdaq Globe Newswire 13 Apr 2026

Key market opportunities for BCMA-targeted therapies include rising multiple myeloma cases, ...

Edit

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy (Form 8-K) (Caribou Biosciences Inc)

Public Technologies 01 Apr 2026

-- Ongoing dose expansion enrollment in CaMMouflage phase 1 clinical trial includes BCMA-naïve and BCMA-exposed cohorts; initial dose expansion and longer follow up on dose escalation data expected in 2026 --.

Edit

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy (Caribou Biosciences Inc)

Public Technologies 01 Apr 2026

Article Search

tools

You can search using any combination of the items listed below.

Language:

Sort:

Indexed:

Search:

Duplicates: